ActoGeniX, (Belgium) is developing a pipeline of therapeutic products based on its TopAct™ technology platform with it’s most advanced candidate for Crohn’s disease, closed a $26M Series A led by GIMV and Life Sciences Partners. New investors include Aescap, Ventech and Baekeland Fonds.
ActoGeniX, NV: Series A $26M
February 20, 2007
Leave a Comment » | 
I - Series A, R - INTERNATIONAL, X - Crohns | 
Permalink
Posted by arubenstein
